Table 1.
Clinical characteristics and outcomes.
Table 2.
Laboratory parameters at baseline.
Fig 1.
Trends of MR-proADM, CPR, PCT, LDH, D-dimer, lymphocytes and NT-proBNP from ICU admission (day 0) to day 14 in survivor (white) and non-survivor (grey) patients.
Time dependent analysis of MR-proADM, CRP and LDH were significantly different between survivors and non-survivors (p-value <0.0001, 0.04 and 0.0253, respectively) and over the time (p-value 0.0193, 0.0003 and 0.0095, respectively), while lymphocytes differed only between survivors and non-survivors (p-value 0.0463). List of abbreviations: MR-proADM: mid-regional pro-adrenomedullin; CRP: C-reactive protein; LDH: lactate dehydrogenase; PCT: procalcitonin; NT-proBNP: N-terminal prohormone of brain natriuretic peptide.
Fig 2.
Stratification of patients with mid-regional pro-adrenomedullin (MR-proADM) levels greater or less than 1.8 nmol/L at ICU admission.
Table 3.
Multivariate logistic regression analysis for mortality.
Fig 3.
Trends of mid-regional pro-adrenomedullin (MR-proADM) from ICU admission (day 0) to day 14 in survivor (white) and non-survivor (grey) patients who required VV-ECMO.
Time dependent analysis of MR-proADM was significantly different between survivors and non-survivors (p-value 0.042) but it was not over the time (p-value 0.205).
Fig 4.
ROC curves of MR-proADM, PCT, CRP, NT-proBNP, LDH and D-dimer and their comparison for predicting mortality.
List of abbreviations: MR-proADM: mid-regional pro-adrenomedullin; PCT: procalcitonin; CRP: C-reactive protein; NT-proBNP: N-terminal prohormone of brain natriuretic peptide; LDH: lactate dehydrogenase; AUC: area under the curve; CI: confidence interval.